RESUMO
Microbial cell-free DNA (mcfDNA) sequencing is a promising tool to identify infectious pathogens when traditional methods fail to identify the causative agent. We performed a retrospective observational cohort study to evaluate clinical outcomes among pediatric and adult patients who underwent mcfDNA testing. 127 mcfDNA tests were reviewed from 112 patients. Baseline characteristics included 61 (54.5 %) adults, 52 (40.9 %) tests were from female patients, and 67 (52.8 %) tests were obtained from patients designated as immunocompromised. Of all tests obtained, 59 (46.4 %) were deemed clinically relevant. 41 (32.3 %) of tests also led to a change in antimicrobial management for the corresponding patient. No statistically significant association was ascertained between patient-specific factors and clinically relevant test results. Testing in certain clinical scenarios or high-risk settings may be useful, however further studies are needed to assess the cost-benefit of this approach.
Assuntos
Ácidos Nucleicos Livres , Doenças Transmissíveis , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Feminino , Estudos Retrospectivos , Sequenciamento de Nucleotídeos em Larga Escala/métodos , Masculino , Adulto , Criança , Pessoa de Meia-Idade , Adolescente , Ácidos Nucleicos Livres/sangue , Pré-Escolar , Adulto Jovem , Doenças Transmissíveis/diagnóstico , Doenças Transmissíveis/tratamento farmacológico , Doenças Transmissíveis/microbiologia , Idoso , Lactente , Técnicas de Diagnóstico Molecular/métodos , Idoso de 80 Anos ou maisRESUMO
Coccidioidomycosis is a fungal infection with a range of clinical manifestations. Currently used antifungal agents exhibit variable efficacy and toxicity profiles that necessitate evaluation of additional therapeutic options. Improvement was observed in the majority of patients treated with isavuconazole, with clinical failures observed only in those with coccidioidal meningitis.
Assuntos
Coccidioidomicose , Humanos , Coccidioidomicose/tratamento farmacológico , Coccidioidomicose/microbiologia , Coccidioides , Triazóis/uso terapêutico , Antifúngicos/uso terapêuticoRESUMO
Mpox has recently re-emerged as a global entity of concern. We report one of the first pediatric cases in the United States and provide updated recommendations relevant to infection control and prevention measures of those in close contact with mpox.